Abstract
CYTOTOXIC T lymphocytes (CTL) constitute an essential part of the immune response against viral infections1. Such CTL recognize peptides derived from viral proteins together with major histocompatibility complex (MHC) class I molecules on the surface of infected cells2–4, and usually require in vivo priming with infectious virus5. Here we report that synthetic viral peptides covalently linked to tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS) can efficiently prime influenza-virus-specific CTL in vivo. These lipopeptides are able to induce the same high-affinity CTL as does the infectious virus. Our data are not only relevant to vaccine development, but also have a bearing on basic immune processes leading to the transition of virgin T cells to activated effector cells in vivo, and to antigen presentation by MHC class I molecules.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brenan, M. Immun. Today 4, 319–320 (1983).
Zinkernagel, R. M. & Doherty, P. C. Nature 248, 701–702 (1974).
Townsend, A. R. M. et al. Cell 44, 959–968 (1986).
Bjorkman, P. J. et al. Nature 329, 512–518 (1987).
Braciale, T. J. & Yap, K. L. J. exp. Med. 147, 1236–1252 (1978).
Bodmer, H. C., Pemberton, R. M., Rothbard, J. B. & Askonas, B. A., Cell 52, 253–248 (1988).
Germain, R. Nature 322, 687–689 (1986).
Bevan M. J. Nature 325, 192–194 (1987).
Lafferty, K. J., Andrus, L. & Prowse, S. J. Immunol. Rev. 61, 279–314 (1980).
Braun, V. Biochim. biophys. Acta 415, 335–377 (1975).
Wolf, B. et al. Immunol. Lett. 20, 121–126 (1989).
Hofmann, P. et al. Immunobiology 177, 158–170 (1988).
Taylor, P. M., Davey, J., Howland, K., Rothbard, J. B., Askonas, B. A. Immumgenetics 26, 267–272 (1987).
Carbone, F. R., Moore, M. W., Sheil, J. M. & Bevan, M. J. J. exp. Med. 167, 1767–1779 (1988).
Moore, M. W., Carbone, F. R. & Bevan, M. J. Cell 54, 777–785 (1988).
Staerz, U. D., Karasuyama, H. & Garner, A. G. Nature 329, 449–451 (1987).
Carbone, F. R. & Bevan, M. J. J. exp. Med. 169, 603–512 (1989).
Wiesmüller, K.-H., Jung, G. & Hess, G. Vaccine 7, 29–33 (1989).
Wiesmüller, K.-H., Bessler, W. G. & Jung, G. Hoppe-Seyler's Z. physiol. Chem. 364, 593–606 (1983).
Jung, G., Wiesmüller, K.-H., Becker, G., Bühring, H.-J. & Bessler, W. G. Angew. Chem 24, 872–873 (1985).
Krug, M. et al. Biopolymers 28, 499–512 (1989).
Lex, A., Wiesmüller, K.-H., Jung, G. & Bessler, W. G. J. Immun. 137, 2676–2681 (1986).
Schild, H. et al. Eur. J. Immun. 17, 1863–1866 (1989).
Zweerink, H. J. et al. Eur. J. Immun. 7, 630–635 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deres, K., Schild, H., Wiesmüller, KH. et al. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342, 561–564 (1989). https://doi.org/10.1038/342561a0
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1038/342561a0
This article is cited by
-
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer
Journal for ImmunoTherapy of Cancer (2019)
-
Personalized cancer vaccines: adjuvants are important, too
Cancer Immunology, Immunotherapy (2018)
-
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Nature Reviews Cancer (2016)
-
Recent advances in the molecular design of synthetic vaccines
Nature Chemistry (2015)
-
Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection
Medical Microbiology and Immunology (2015)
